Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics

Abstract INTRODUCTION With the advent of disease‐modifying therapies, accurate assessment of biomarkers indicating the presence of disease‐associated amyloid beta (Aβ) pathology becomes crucial in patients with clinically suspected Alzheimer's disease (AD). We evaluated Aβ levels in cerebrospinal fl...

Descripció completa

Dades bibliogràfiques

Autors principals:	Matthias Brendel, Tandis Parvizi, Johannes Gnörich, Christof Elias Topfstedt, Katharina Buerger, Daniel Janowitz, Boris‐Stephan Rauchmann, Robert Perneczky, Carolin Kurz, Dirk Mehrens, Wolfgang G. Kunz, Julia Kusche‐Palenga, Agnes Bernadette Kling, Antonia Buchal, Elizabet Nestorova, Sara Silvaieh, Raphael Wurm, Tatjana Traub‐Weidinger, Sigrid Klotz, Günther Regelsberger, Axel Rominger, Alexander Drzezga, Johannes Levin, Elisabeth Stögmann, Nicolai Franzmeier, Günter U. Höglinger
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-10-01
Col·lecció:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Matèries:	Alzheimer's disease biomarkers cerebrospinal fluid dementia positron emission tomography real world
Accés en línia:	https://doi.org/10.1002/dad2.70031
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!